News | July 10, 2024
Lilly to acquire Morphic to improve outcomes for patients with inflammatory bowel disease
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
Globally, colorectal cancer impacts 1.9 million people each year, standing as a leading cause of cancer mortality
Dr. Roopal Thakkar joined Abbott/AbbVie in 2003 as part of the Physician Development Program
Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
Submission based on positive SUPERNOVA Phase III trial data which demonstrated a statistically significant reduction in the incidence of COVID?19 in an immunocompromised patient population
Offering testing, treatment and support to help stop the spread of HIV and other infectious diseases
Imfinzi also recommended for patients with mismatch repair deficient disease
First immunotherapy regimen before and after surgery to extend survival in bladder cancer
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
Subscribe To Our Newsletter & Stay Updated
